Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic
Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients with
Type 2 Diabetes Mellitus